Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,029 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).
Watanabe K, Niikura N, Kikawa Y, Oba M, Kobayashi K, Tada H, Ozaki S, Toh U, Yamamoto Y, Tsuneizumi M, Okuno T, Iwakuma N, Takeshita T, Iwamoto T, Ishiguro H, Masuda N, Saji S. Watanabe K, et al. Among authors: kobayashi k. Breast Cancer Res Treat. 2023 Jun;199(2):253-263. doi: 10.1007/s10549-023-06911-5. Epub 2023 Mar 31. Breast Cancer Res Treat. 2023. PMID: 37000345 Free PMC article.
Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience.
Ishida N, Araki K, Sakai T, Kobayashi K, Kobayashi T, Fukada I, Hosoda M, Yamamoto M, Ichinokawa K, Takahashi S, Iwase T, Ito Y, Yamashita H. Ishida N, et al. Among authors: kobayashi k, kobayashi t. Breast Cancer. 2016 Jul;23(4):617-23. doi: 10.1007/s12282-015-0612-0. Epub 2015 Apr 21. Breast Cancer. 2016. PMID: 25896598 Free article. Clinical Trial.
Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
Araki K, Ito Y, Fukada I, Kobayashi K, Miyagawa Y, Imamura M, Kira A, Takatsuka Y, Egawa C, Suwa H, Ohno S, Miyoshi Y. Araki K, et al. Among authors: kobayashi k. BMC Cancer. 2018 Oct 16;18(1):982. doi: 10.1186/s12885-018-4888-2. BMC Cancer. 2018. PMID: 30326862 Free PMC article.
Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients.
Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Kawahara T, Ohashi Y, Mukai H; RESPECT study group. Sawaki M, et al. Among authors: kobayashi k. J Clin Oncol. 2020 Nov 10;38(32):3743-3752. doi: 10.1200/JCO.20.00184. Epub 2020 Sep 16. J Clin Oncol. 2020. PMID: 32936713 Clinical Trial.
Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer.
Taira N, Sawaki M, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Ohashi Y, Mukai H, Kawahara T; RESPECT Study Group. Taira N, et al. Among authors: kobayashi k. J Clin Oncol. 2021 Aug 1;39(22):2452-2462. doi: 10.1200/JCO.20.02751. Epub 2021 Apr 9. J Clin Oncol. 2021. PMID: 33835842
Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial.
Hagiwara Y, Sawaki M, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, Takahashi M, Saito T, Baba S, Kobayashi K, Mukai H, Taira N. Hagiwara Y, et al. Among authors: kobayashi k. Breast Cancer Res Treat. 2021 Aug;188(3):675-683. doi: 10.1007/s10549-021-06253-0. Epub 2021 Jun 2. Breast Cancer Res Treat. 2021. PMID: 34080094 Clinical Trial.
Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.
Ozaki Y, Aoyama Y, Masuda J, Inagaki L, Kawai S, Shibayama T, Maeda T, Kurata M, Yoshida K, Saeki S, Hosonaga M, Fukada I, Hara F, Kobayashi T, Kobayashi K, Miyake S, Takano T, Ueno T, Ohno S. Ozaki Y, et al. Among authors: kobayashi k, kobayashi t. BMC Cancer. 2022 Jan 4;22(1):36. doi: 10.1186/s12885-021-09128-1. BMC Cancer. 2022. PMID: 34983437 Free PMC article.
Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer.
Chin YM, Shibayama T, Chan HT, Otaki M, Hara F, Kobayashi T, Kobayashi K, Hosonaga M, Fukada I, Inagaki L, Ono M, Ito Y, Takahashi S, Ohno S, Ueno T, Nakamura Y, Low SK. Chin YM, et al. Among authors: kobayashi k, kobayashi t. Cancer Sci. 2022 May;113(5):1808-1820. doi: 10.1111/cas.15304. Epub 2022 Mar 9. Cancer Sci. 2022. PMID: 35201661 Free PMC article.
Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.
Masuda N, Ono M, Mukohara T, Yasojima H, Shimoi T, Kobayashi K, Harano K, Mizutani M, Tanioka M, Takahashi S, Kogawa T, Suzuki T, Okumura S, Takase T, Nagai R, Semba T, Zhao ZM, Ren M, Yonemori K. Masuda N, et al. Among authors: kobayashi k. Eur J Cancer. 2022 Jun;168:108-118. doi: 10.1016/j.ejca.2022.03.004. Epub 2022 Apr 29. Eur J Cancer. 2022. PMID: 35500404 Free article. Clinical Trial.
12,029 results
You have reached the last available page of results. Please see the User Guide for more information.